- IN₹627.10bn
- IN₹765.36bn
- IN₹169.27bn
Brief: Biocon Secures 10-Year Supply Contract For Pertuzumab In Brazil
Brief: Biocon Unit Gets Pegfilgrastim Biosimilar Marketing Approval By Japan
India's Biocon rises after FDA approves Yesintek autoinjector in US
Brief: Biocon Announces U.S. FDA Approval For Yesintek Single-Dose Prefilled Autoinjector
India's Biocon rises after quarterly profit more than quadruples
India Stocks: India shares inch higher at the open on Middle East peace prospects, earnings
India Stocks: India shares seen higher on Mideast peace prospects, earnings
India's Biocon posts more than fourfold jump in quarterly profit on strong biosimilars growth
Brief: Biocon June-Quarter Consol Net Profit 1.41 Billion Rupees
Brief: Biocon Announces U.S. Commercial Launch Of Yesafili™
Brief: Biocon Announces Commercial Launch Of Yesafili In The United States
Roche sues Biocon over proposed breast-cancer drug copy (updated)
Roche sues Biocon over proposed breast-cancer drug copy
Brief: Biocon Says Biocon Malaysia Receives EMA Approval For New Drug Product Fill Finish Unit For Insulins
India's Biocon gains on European approval for new production line at Malaysia facility
Brief: Mylan Inc Sells 46 Million Biocon Shares For 400 Rupees/Share Via Block Deals - BSE Data
India's Biocon gains after block deal
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows (updated)
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows